<DOC>
	<DOCNO>NCT01445600</DOCNO>
	<brief_summary>This open label , multi-centre , non-interventional post-marketing surveillance .</brief_summary>
	<brief_title>ALTARGO ( Retapamulin ) PMS ( Post-marketing Surveillance )</brief_title>
	<detailed_description>This open label , multi-centre , non-interventional post-marketing surveillance monitor safety ALTARGO ( retapamulin ) treat Korean patient accord prescribe information . ALTARGO trademark GlaxoSmithKline group company .</detailed_description>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>All subject must satisfy follow criterion study entry : 1 . Subjects administer ALTARGO ( retapamulin ) topical treatment follow bacterial skin skin structure infection ( SSSI ) 2 . Subjects investigator believe comply requirement protocol follow administration regimen 3 . Subjects administer ALTARGO ( retapamulin ) follow locally approve prescribe information Considering nature observational study , GSK Korea encourage doctor participate study enrol subject prescribe retapamulin follow locally approve Prescribing Information . 1 . Subjects know suspected hypersensitivity ALTARGO ( retapamulin ) component ointment 2 . Infants nine month age</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Impetigo</keyword>
	<keyword>secondarily-infected traumatic lesion</keyword>
	<keyword>retapamulin</keyword>
</DOC>